Genmab spent more than DKK 1 billion in Q1
Genmab's research and development projects have been costly in the first quarter, but the Danish biotech firm's profit has quadrupled. It maintains its guidance.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The first quarter of the year has gone according to plan for the Danish biotech firm Genmab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen had better Darzalex sales than expected in Q1
For subscribers
